Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon Clearance is Preserved in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Distinct Molecular Signatures of Clinical Clusters in People with Type 2 Diabetes: an IMI-RHAPSODY Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differential DNA Methylation and Expression of miRNAs in Adipose Tissue From Twin Pairs Discordant for Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The low-expression variant of FABP4 is associated with cardiovascular disease in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The aim of our study was to evaluate whether inhibition of ACE (lisinopril 10-20 mg/day) can reduce the rate of decline in kidney function more than reducing blood pressure with conventional antihypertensive treatment (atenolol 50-100 mg/day), usually in combination with a diuretic. We performed a prospective, randomized, parallel study for 42 months, double blind for the first 12 months and single blind thereafter. Forty-three (21 lisinopril and 22 atenolol) hypertensive NIDDM patients with diabetic nephropathy were enrolled. Data from 36 patients (17 lisinopril and 19 atenolol, 60 +/- 7 years of age, 27 men) who completed at least 12 months of the study period are presented. At baseline, the two groups were comparable: glomerular filtration rate (51Cr-EDTA plasma clearance) was 75 +/- 6 and 74 +/- 8 ml x min(-1) x 1.73 m(-2), mean 24-h ambulatory blood pressure (A&D TM2420) was 110 +/- 3 and 114 +/- 2 mmHg, and 24-h urinary albumin excretion rate was 961 (range 331-5,727) and 1,578 (476-5,806) mg/24 h in the lisinopril and atenolol groups, respectively. The mean follow-up time was similar, 37 and 35 months in the lisinopril and atenolol groups, respectively. Mean ambulatory blood pressure was equally reduced in the two groups, 12 +/- 2 and 10 +/- 2 mmHg in the lisinopril and atenolol groups, respectively. Glomerular filtration rate declined in a biphasic manner with a faster initial (0 to 6 months) change of 1.25 +/- 0.49 and 0.81 +/- 0.29 ml x min(-1) x month(-1) followed by a slower sustained decline (6 to 42 months) of 0.59 +/- 0.10 and 0.54 +/- 0.13 ml x min(-1) x month(-1) in the lisinopril and atenolol groups, respectively. No significant differences were observed in either initial or sustained decline in glomerular filtration rate between the two groups. Urinary albumin excretion was reduced (% reduction of baseline) more in the lisinopril than in the atenolol group, at 55 (95% CI 29-72) and 15% (-13 to 34), respectively (P = 0.01). In conclusion, the relentless decline in kidney function characteristically found in hypertensive NIDDM patients with diabetic nephropathy can be reduced equally effectively by two antihypertensive treatments, the beta-blocker atenolol and the ACE inhibitor lisinopril.

Original languageEnglish
JournalDiabetes
Volume46
Issue number7
Pages (from-to)1182-8
Number of pages7
ISSN0012-1797
Publication statusPublished - Jul 1997

    Research areas

  • Aged, Albuminuria, Angiotensin-Converting Enzyme Inhibitors, Animals, Antihypertensive Agents, Atenolol, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypertension, Renal, Kidney, Lisinopril, Male, Middle Aged, Prospective Studies, Rabbits, Single-Blind Method, Time Factors, Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

ID: 52020418